Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Bulumtatug Furvedotin (Primary)
- Indications Advanced breast cancer; Cervical cancer; HER2 negative breast cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
Most Recent Events
- 04 Jun 2024 Results (n=260) assessing the updated safety and efficacy data of 9MW2821 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 24 May 2024 According to a Mabwell media release, company announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 13 May 2024 Results(n=20) in patients with triple negative breast cancer from this trial presented in a Mabwell media release.